powder and solvent for solution for injection
Triptorelinum
This medicine contains triptorelin. Triptorelin belongs to a group of medicines known as gonadotropin-releasing hormone (GnRH) analogues. One of its actions is to reduce the production of sex hormones in the body.
Long-term administration of triptorelin, after initial stimulation, leads to inhibition of gonadotropin secretion, which in turn leads to inhibition of gonadal function (testes or ovaries).
Prostate cancer with metastases
Administration of a single dose of the medicine may initially increase testosterone levels. Continued treatment leads to a decrease in steroid hormone levels within 2-3 weeks to a level equivalent to castration. This condition depends on the duration of treatment.
Infertility in women
Long-term treatment with the preparation leads to inhibition of gonadotropin secretion. This treatment improves the course of folliculogenesis, increasing the number of maturing follicles, which leads to an increased number of pregnancies per cycle.
Indications for use of Diphereline 0.1 mg
Before starting treatment with Diphereline 0.1 mg, discuss it with your doctor or pharmacist.
During treatment with Diphereline 0.1 mg, a pituitary tumor (benign tumor) may be revealed, which the patient was not aware of. Symptoms include sudden headache, vomiting, vision disturbances, and eye muscle paralysis.
There have been reports of depression, including severe depression, in patients taking Diphereline 0.1 mg. If depressive moods occur while taking Diphereline 0.1 mg, inform your doctor.
In adults, long-term treatment with triptorelin may cause bone weakness (osteoporosis) associated with an increased risk of bone fractures. Inform your doctor if you have any of the following risk factors, as your doctor may recommend taking bisphosphonates (medicines used to treat osteoporosis) to treat bone loss.
Risk factors may include:
If seizures occur, inform your doctor immediately. Seizures have been reported in patients taking triptorelin or similar medicines. They occurred in patients with previously diagnosed epilepsy or without it.
Men
At the beginning of treatment, an increase in testosterone levels in the body is observed. This may cause worsening of symptoms related to the tumor. In such a case, contact your doctor. Your doctor may prescribe an additional medicine (anti-androgen) to prevent worsening of these symptoms.
If the patient experiences urinary retention or spinal cord compression due to tumor spread, the doctor will closely monitor the patient during the first few weeks of treatment. In case of difficulty urinating, bone pain, lower limb weakness, or tingling, contact your doctor immediately, who will assess the patient's condition and initiate appropriate treatment.
Triptorelin does not induce further reduction of testosterone levels in patients after orchiectomy (testicle removal).
Results of diagnostic tests of gonadal pituitary and reproductive organ function performed during or after treatment with Diphereline 0.1 mg may be misleading.
Inform your doctor if you have heart or blood vessel disease, including arrhythmias (abnormal heart rhythm) or if you are taking medicines used to treat arrhythmias. The risk of arrhythmias may be increased during treatment with Diphereline 0.1 mg.
Medicines that lower testosterone levels may cause changes in the ECG related to arrhythmias (prolongation of the QT interval).
Inform your doctor if you have diabetes and/or heart disease.
Women
During treatment for infertility, gonadotropins in combination with Diphereline 0.1 mg may cause ovarian enlargement or hyperstimulation, which may cause pelvic and/or abdominal pain and breathing difficulties. In such a case, consult your doctor immediately.
Tell your doctor or pharmacist about all medicines you are currently taking or have recently taken, as well as any medicines you plan to take.
Men:
Diphereline 0.1 mg may affect the action of other medicines used to treat arrhythmias (e.g., quinidine, procainamide, amiodarone, sotalol) or may increase the risk of arrhythmias when taken with other medicines (e.g., methadone used to treat pain and as part of detoxification in case of drug addiction), moxifloxacin (antibiotic), antipsychotic medicines used to treat severe mental illnesses).
If you are pregnant or breastfeeding, think you may be pregnant, or plan to have a child, consult your doctor before using this medicine.
It must be confirmed that the patient is not pregnant before prescribing Diphereline 0.1 mg.
Diphereline 0.1 mg must not be used during pregnancy and breastfeeding.
During treatment, dizziness, fatigue, or vision problems, such as blurred vision, may occur. These symptoms may be side effects of treatment or the underlying disease. If any of these side effects occur, do not drive or operate any machines.
The medicine contains less than 1 mmol (23 mg) of sodium per dose, which means the medicine is considered "sodium-free".
The medicine is administered subcutaneously.
Prostate cancer with metastases
One subcutaneous injection of Diphereline 0.1 mg once a day for 7 days before using a prolonged-release form.
Infertility in women
Administer subcutaneously one dose of the medicine (0.1 mg) per day from the second day of the cycle. After achieving decreased pituitary sensitivity (i.e., around the 15th day from the start of treatment), gonadotropin stimulation is started and continued while administering triptorelin until the day before the scheduled day of hCG administration (chorionic gonadotropin).
Method of preparation of the medicine:
Transfer the solvent to the vial containing the powder. Shake until completely dissolved and administer immediately.
Used syringes should be disposed of in a suitable container for sharp objects. Any remaining medicine should be disposed of.
No side effects have been observed after overdose of the medicine.
Like all medicines, Diphereline 0.1 mg can cause side effects, although not everybody gets them.
In rare cases, a severe allergic reaction may occur. If symptoms such as difficulty swallowing or breathing, swelling of the lips, face, throat, or tongue, rash, or dizziness occur, inform your doctor immediately.
Men
Many of the side effects are likely to be caused by changes in testosterone levels in the body. These effects include: hot flashes, impotence, and decreased libido.
Very common- side effects that occur in more than 1 in 10 patients
Common- side effects that occur in no more than 1 in 10 patients
Uncommon- side effects that occur in no more than 1 in 100 patients
Rare- side effects that occur in no more than 1 in 1000 patients
Side effects reported after the medicine was placed on the market (frequency not known):
As with other GnRH analogues, patients treated with Diphereline 0.1 mg may have an increased white blood cell count.
Women
Many of the side effects are likely to be caused by changes in estrogen levels in the body.
Very common- side effects that occur in more than 1 in 10 patients
Common- side effects that occur in no more than 1 in 10 patients
Uncommon- side effects that occur in no more than 1 in 100 patients
Side effects reported after the medicine was placed on the market (frequency not known):
During treatment for infertility, gonadotropins in combination with Diphereline 0.1 mg may cause pelvic and/or abdominal pain and shortness of breath. If such symptoms occur, inform your doctor immediately.
If you experience any side effects, including any not listed in this leaflet, tell your doctor or pharmacist, or nurse. Side effects can be reported directly to the Department of Monitoring of Adverse Reactions to Medicinal Products of the Office for Registration of Medicinal Products, Medical Devices, and Biocidal Products
Al. Jerozolimskie 181C
02-222 Warsaw
Phone: +48 22 49 21 301
Fax: +48 22 49 21 309
Website: https://smz.ezdrowie.gov.pl
Side effects can also be reported to the marketing authorization holder.
By reporting side effects, you can help provide more information on the safety of this medicine.
Store the medicine out of sight and reach of children.
Do not use this medicine after the expiry date stated on the carton. The expiry date refers to the last day of that month.
Expiry date (EXP)
Batch number (Lot)
Store in a temperature below 25°C.
The active substance of the medicine is triptorelin in the form of triptorelin acetate. One vial contains 0.1 mg of triptorelin.
Other ingredients are:
Powder and solvent for solution for injection.
A glass vial containing powder and a glass ampoule containing solvent.
The pack contains 7 vials of powder and 7 ampoules of solvent.
Marketing authorization holder
Ipsen Pharma
65 Quai Georges Gorse
92100 Boulogne Billancourt
France
Manufacturer
Ipsen Pharma Biotech
Parc d’Activités du Plateau de Signes
Chemin départemental nr 402
83870 Signes
France
To obtain more detailed information about this medicine, contact the local representative of the marketing authorization holder:
Ipsen Poland Sp. z o.o.
ul. Chmielna 73
00-801 Warsaw
phone: 22 653 68 00
fax: 22 653 68 22
Date of last revision of the leaflet:October 2024
Need help understanding this medicine or your symptoms? Online doctors can answer your questions and offer guidance.